Shares of Becton Dickinson & Co. BDX sank 0.47% to $224.10 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.39% to 5,893. ...

Shareholders of Becton, Dickinson & Co (Symbol: BDX) looking to boost their income beyond the stock's 1.8% annualized dividend yield can sell the March 2025 covered call at the $240 strike and ...

Becton, Dickinson and Company is projected to achieve 8.8%-9.3% revenue growth in FY25, driven by new product launches and the APM business. The acquisition of Edwards Lifesciences' Critical Care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton, Dickinson and Company announced a strategic collaboration with Ypsomed, a developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs.

Becton Dickinson (BDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

With a market cap of $68.8 billion, Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a leading global medical technology firm. It develops and supplies medical devices ...

Based in Franklin Lakes, NJ, Becton, Dickinson and Company, commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices ...

Hello and welcome to BD's Fourth Quarter and Full Year Fiscal 2024 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations ...

Becton Dickinson's fiscal fourth-quarter earnings rose sharply as the acquisition of Edward Lifesciences' critical-care supply unit bolstered revenue growth. For the quarter ended Sept.

In this article, we are going to take a look at where Becton, Dickinson and Company (NYSE:BDX) stands against other most promising medical stocks. The healthcare sector depends on medical ...